{
    "id": 2147,
    "fullName": "SMARCB1 negative",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "SMARCB1 negative indicates a lack of the SMARCB1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6598,
        "geneSymbol": "SMARCB1",
        "terms": [
            "SMARCB1",
            "BAF47",
            "CSS3",
            "hSNFS",
            "INI1",
            "MRD15",
            "PPP1R144",
            "RDT",
            "RTPS1",
            "Sfh1p",
            "SNF5",
            "SNF5L1",
            "Snr1",
            "SWNTS1"
        ]
    },
    "variant": "negative",
    "createDate": "10/09/2014",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5768,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited growth of SMARCB1-negative malignant rhabdoid tumor cell lines in culture, and sensitivity was associated with low levels of p16 expression (PMID: 21871868).",
            "molecularProfile": {
                "id": 2085,
                "profileName": "SMARCB1 negative"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3672,
                "name": "rhabdoid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5148,
                    "pubMedId": 21871868,
                    "title": "Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21871868"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5766,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DZNep increased radiosensitivity in SMARCB1-negative atypical teratoid rhabdoid tumor cell lines in culture (PMID: 23190500).",
            "molecularProfile": {
                "id": 2085,
                "profileName": "SMARCB1 negative"
            },
            "therapy": {
                "id": 3924,
                "therapyName": "DZNeP + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 2129,
                "name": "atypical teratoid rhabdoid tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5147,
                    "pubMedId": 23190500,
                    "title": "Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23190500"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12688,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tazemetostat (EPZ-6438) was well-tolerated and demonstrated anti-tumor activity in pediatric patients with SMARCB1 (INI)-deficient tumors, including complete or partial responses in patients with epithelioid sarcoma (n=1), chordoma (n=2), and atypical teratoid rhaboid tumor (n=1) (AACR-NCI-EORTC Int Conference on Molecular Targets and Cancer Therapeutics 2017, A175; NCT02601937).",
            "molecularProfile": {
                "id": 2085,
                "profileName": "SMARCB1 negative"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 3302,
                "name": "chordoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10601,
                    "pubMedId": null,
                    "title": "A175 / 175 - Phase 1 study of the EZH2 inhibitor, tazemetostat, in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma",
                    "url": "http://www.abstractsonline.com/pp8/#!/4557/presentation/282"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19611,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tazemetostat (EPZ-6438) demonstrated safety and preliminary efficacy, resulted in clinical benefit (stable disease or better) in 38% (5/13) of patients with SMARCB1 or AMARCA4-negative advanced solid tumors (PMID: 29650362; NCT01897571).",
            "molecularProfile": {
                "id": 2085,
                "profileName": "SMARCB1 negative"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17176,
                    "pubMedId": 29650362,
                    "title": "Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650362"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12686,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tazemetostat (EPZ-6438) was well-tolerated and demonstrated anti-tumor activity in pediatric patients with SMARCB1 (INI)-deficient tumors, including complete or partial responses in patients with epithelioid sarcoma (n=1), chordoma (n=2), and atypical teratoid rhaboid tumor (n=1) (AACR-NCI-EORTC Int Conference on Molecular Targets and Cancer Therapeutics 2017, A175; NCT02601937).",
            "molecularProfile": {
                "id": 2085,
                "profileName": "SMARCB1 negative"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 2129,
                "name": "atypical teratoid rhabdoid tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10601,
                    "pubMedId": null,
                    "title": "A175 / 175 - Phase 1 study of the EZH2 inhibitor, tazemetostat, in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma",
                    "url": "http://www.abstractsonline.com/pp8/#!/4557/presentation/282"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5764,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Zolinza (vorinostat) and fenretinide induced apoptosis and inhibited growth of rhabdoid tumor cell lines in culture (PMID: 23764045).",
            "molecularProfile": {
                "id": 2085,
                "profileName": "SMARCB1 negative"
            },
            "therapy": {
                "id": 3923,
                "therapyName": "Fenretinide + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 3672,
                "name": "rhabdoid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5146,
                    "pubMedId": 23764045,
                    "title": "The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23764045"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19615,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tazemetostat (EPZ-6438) demonstrated safety and preliminary efficacy, resulted durable stable disease in 2 patients with SMARCB1-negative epithelioid sarcoma (PMID: 29650362; NCT01897571).",
            "molecularProfile": {
                "id": 2085,
                "profileName": "SMARCB1 negative"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 6193,
                "name": "epithelioid sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17176,
                    "pubMedId": 29650362,
                    "title": "Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650362"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20007,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tazverik (tazemetostat) treatment resulted in an objective response rate of 15% (9/62) and a disease control rate of 26% (16/62) in patients with locally advanced or metastatic SMARCB1 (INI1)-negative epithelioid sarcoma, with a median duration of response not reached and a median overall survival of 82.4 weeks (J Clin Oncol 37, no. 15_suppl (May 20, 2019) 11003-11003, NCT02601950).",
            "molecularProfile": {
                "id": 2085,
                "profileName": "SMARCB1 negative"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 6193,
                "name": "epithelioid sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17653,
                    "pubMedId": null,
                    "title": "Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.11003"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12687,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tazemetostat (EPZ-6438) was well-tolerated and demonstrated anti-tumor activity in pediatric patients with SMARCB1 (INI)-deficient tumors, including complete or partial responses in patients with epithelioid sarcoma (n=1), chordoma (n=2), and atypical teratoid rhaboid tumor (n=1) (AACR-NCI-EORTC Int Conference on Molecular Targets and Cancer Therapeutics 2017, A175; NCT02601937).",
            "molecularProfile": {
                "id": 2085,
                "profileName": "SMARCB1 negative"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 6193,
                "name": "epithelioid sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10601,
                    "pubMedId": null,
                    "title": "A175 / 175 - Phase 1 study of the EZH2 inhibitor, tazemetostat, in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma",
                    "url": "http://www.abstractsonline.com/pp8/#!/4557/presentation/282"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1181,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alvocidib (flavopiridol) induced cell-cycle arrest and inhibited growth of human rhabdoid tumor cell lines with SMARCB1 biallelic deficiency in culture and inhibted tumor growth in SMARCB1-deficient cell line xenograft models (PMID: 18223228).",
            "molecularProfile": {
                "id": 2085,
                "profileName": "SMARCB1 negative"
            },
            "therapy": {
                "id": 628,
                "therapyName": "Alvocidib",
                "synonyms": null
            },
            "indication": {
                "id": 3672,
                "name": "rhabdoid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 923,
                    "pubMedId": 18223228,
                    "title": "Rhabdoid tumor growth is inhibited by flavopiridol.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18223228"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19613,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tazemetostat (EPZ-6438) demonstrated safety and preliminary efficacy, resulted in a durable complete response lasting over 2.3 years in a patient with SMARCB1-negative malignant rhabdoid tumor (PMID: 29650362; NCT01897571).",
            "molecularProfile": {
                "id": 2085,
                "profileName": "SMARCB1 negative"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 3672,
                "name": "rhabdoid cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17176,
                    "pubMedId": 29650362,
                    "title": "Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650362"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5765,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DZNep induced apoptosis and cell-cycle arrest and inhibited growth of SMARCB1-negative atypical teratoid rhabdoid tumor cell lines in culture (PMID: 23190500).",
            "molecularProfile": {
                "id": 2085,
                "profileName": "SMARCB1 negative"
            },
            "therapy": {
                "id": 2702,
                "therapyName": "DZNeP",
                "synonyms": null
            },
            "indication": {
                "id": 2129,
                "name": "atypical teratoid rhabdoid tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5147,
                    "pubMedId": 23190500,
                    "title": "Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23190500"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5767,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDKN2A (p16) over expression was associated with decreased sensitivity to Ibrance (palbociclib) in a SMARCB1-negative malignant rhabdoid tumor cell line in culture (PMID: 21871868).",
            "molecularProfile": {
                "id": 21572,
                "profileName": "CDKN2A over exp SMARCB1 neg"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3672,
                "name": "rhabdoid cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5148,
                    "pubMedId": 21871868,
                    "title": "Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21871868"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2085,
            "profileName": "SMARCB1 negative",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21572,
            "profileName": "CDKN2A over exp SMARCB1 neg",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}